कनाडा - अंग्रेज़ी - Health Canada

pro doc limitee - nifedipine - tablet (extended-release) - 60mg - nifedipine 60mg - dihydropyridines

कनाडा - अंग्रेज़ी - Health Canada

pharmascience inc - nifedipine - tablet (extended-release) - 20mg - nifedipine 20mg - dihydropyridines

कनाडा - अंग्रेज़ी - Health Canada

pro doc limitee - nifedipine - tablet (extended-release) - 20mg - nifedipine 20mg - dihydropyridines

कनाडा - अंग्रेज़ी - Health Canada

angita pharma inc. - nifedipine - tablet (extended-release) - 60mg - nifedipine 60mg - dihydropyridines

कनाडा - अंग्रेज़ी - Health Canada

mantra pharma inc - nifedipine - tablet (extended-release) - 60mg - nifedipine 60mg - dihydropyridines

कनाडा - अंग्रेज़ी - Health Canada

jamp pharma corporation - nifedipine - tablet (extended-release) - 60mg - nifedipine 60mg - dihydropyridines

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - eplerenone -

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - eplerenone -

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - eplerenone, quantity: 25 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium lauryl sulfate; hypromellose; magnesium stearate; macrogol 400; titanium dioxide; microcrystalline cellulose; polysorbate 80; iron oxide red; iron oxide yellow; purified talc; croscarmellose sodium - eplerenone is indicated: - to reduce the risk of cardiovascular death in combination with standard therapy in patients who have evidence of heart failure and left ventricular impairment within 3-14 days of an acute myocardial infarction (see clinical trials and dosage and administration). ; - to reduce the risk of cardiovascular mortality and morbidity in adult patients with nyha class ii (chronic) heart failure and left ventricular systolic dysfunction (lvef less than or equal to 30% or lvef less than or equal to 35% in addition to qrs duration of greater than 130 msec), in addition to standard optimal therapy (see clinical trials).